Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 6, 2015, Pages 1118-1124.e3

  Yarur, Andres J ^a   Kubiliun, Maddie J ^a   Czul, Frank ^a   Sussman, Daniel A ^a   Quintero, Maria A ^a   Jain, Anjali ^b   Drake, Katherine A ^b   Hauenstein, Scott I ^b   Lockton, Steven ^b   Deshpande, Amar R ^a   Barkin, Jamie S ^a   Singh, Sharat ^b   Abreu, Maria T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Prometheus Laboratories   (United States)

Author keywords

Azathioprine; Crohn's Disease; Drug Levels; Mercaptopurine; Ulcerative Colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DRUG ANTIBODY; DRUG METABOLITE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; TIOGUANINE; 6-THIOGUANYLIC ACID; ANTIBODY; GUANINE NUCLEOTIDE; IMMUNOLOGIC FACTOR; NUCLEOTIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COMPETITION; ERYTHROCYTE LEVEL; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; MONOTHERAPY; PREDICTION; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNITED STATES; BLOOD; CHEMISTRY; COMBINATION DRUG THERAPY; INFLAMMATORY BOWEL DISEASES; PROCEDURES; SERUM;

ADULT; ANTIBODIES; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; SERUM; THIONUCLEOTIDES;

EID: 84928628450     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.12.026     Document Type: Article

References (30)

1. Ford A.C., Sandborn W.J., Khan K.J., et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:644-659. quiz 660.
2. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. NEngl J Med 2010, 362:1383-1395.
3. Panaccione R., Ghosh S., Middleton S., et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014, 146:392-400.e3.
4. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
5. Kotlyar D.S., Osterman M.T., Diamond R.H., et al. Asystematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9:36-41.e1.
6. Dubinsky M.C., Lamothe S., Yang H.Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705-713.
7. Osterman M.T., Kundu R., Lichtenstein G.R., et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006, 130:1047-1053.
8. Pozler O., Chládek J., Malý J., et al. Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. JCrohns Colitis 2010, 4:623-628.
9. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5-36.
10. Cuffari C., Théorêt Y., Latour S., et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996, 39:401-406.
11. Wang S.-L., Ohrmund L., Hauenstein S., et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. JImmunol Methods 2012, 382:177-188.
12. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
13. Seow C.H., Newman A., Irwin S.P., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
14. Panccione R., Ghosh S., Middleton S., et al. Infliximab, azathioprine, or infliximab+ azathioprine for treatment of moderate to severe ulcerative colitis: the UC Success Trial. Gastroenterology 2011, 140. S-134.
15. Baert F., Drobne D., Gils A., et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation ofinfliximab therapy. Clin Gastroenterol Hepatol 2014, 12:1474-1481.
16. Afif W., Loftus E.V., Faubion W.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
17. Cornillie F., Hanauer S.B., Diamond R.H., et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014, 63:1721-1727.
18. Levesque B.G., Greenberg G.R., Zou G., et al. Aprospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther 2014, 39:1126-1135.
19. Costantino G., Furfaro F., Belvedere A., et al. Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. JCrohns Colitis 2012, 6:588-596.
20. Abbas A., Koleva Y.N., Khan N. Incidence rate of lymphoma by the cumulative duration of exposure to thiopurines: a nationwide retrospective cohort from the Veterans' Affairs Healthcare System. Gastroenterology 2013, 144:S406-S407.
21. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
22. Oussalah A., Chevaux J.-B., Fay R., et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010, 105:1142-1149.
23. Yarur A.J., Strobel S.G., Deshpande A.R., et al. Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2011, 7:652-659.
24. Brouwer A., Horan M.A., Barelds R.J., et al. Cellular aging of the reticuloendothelial system. Arch Gerontol Geriatr 1986, 5:317-324.
25. Nanda K.S., Cheifetz A.S., Moss A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2012, 108:40-47.
26. Hibi T., Sakuraba A., Watanabe M., et al. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. JGastroenterol 2014, 49:254-262.
27. Fasanmade A.A., Adedokun O.J., Blank M., et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011, 33:946-964.
28. Ungar B., Chowers Y., Yavzori M., et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014, 63:1258-1264.
29. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. NEngl J Med 2003, 348:601-608.
30. Wright S. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004, 53:1123-1128.